Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer
Merrimack will also present an analysis of the
Oral Presentation:
- Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) in
NAPOLI -1: A phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy (Abstract O-004)Wednesday, June 29, 2016 ,5:53 - 6:03 PM CEST
Session: Pancreatic Cancer
Poster Presentation Time: Thursday, June 30, 2016, 11:00 - 11:30 AM and 5:10 - 5:40 PM CEST
CCIB, Exhibit Hall
Poster Sessions:
- Safety across subgroups in
NAPOLI -1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy (Abstract PD-023)
Session: Pancreatic Cancer
Poster Discussion Time:Thursday, June 30, 2016 ,11:00 - 11:30 AM CEST
Poster Presentation Time: Thursday, June 30, 2016, 11:00 - 11:30 AM and5:10 - 5:40 PM CEST
CCIB, Exhibit Hall
- Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): A randomized, open-label phase 2 study (Abstract P-287)
Session: Pancreatic Cancer
Poster Presentation Time:Thursday, June 30, 2016 ,11:00 - 11:30 AM and5:10 - 5:40 PM CEST
CCIB, Exhibit Hall
About Merrimack
Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDE® (irinotecan liposome injection), was approved by the U.S. FDA in October 2015. With four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry. For more information, please visit Merrimack's website at www.merrimack.com or connect on Twitter at @MerrimackPharma.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
Contacts:
Media Contact
774-776-1478
mmcmorrow@merrimack.com
Investor Contact
617-441-7602
ggrande@merrimack.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/merrimack-to-present-new-analyses-of-phase-3-napoli-1-data-at-the-esmo-18th-world-congress-on-gastrointestinal-cancer-300288223.html
SOURCE
News Provided by Acquire Media